<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518579</url>
  </required_header>
  <id_info>
    <org_study_id>375</org_study_id>
    <nct_id>NCT04518579</nct_id>
  </id_info>
  <brief_title>Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients With Cancer Colon</brief_title>
  <acronym>tumorimmunity</acronym>
  <official_title>Effect of Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients Undergoing Open Surgery for Cancer Colon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery is the primary treatment for colon cancer. However, the rate of recurrence or&#xD;
      metastasis in colon cancer can be as high as 30%, even in stages 1 and 2 . Most colon&#xD;
      cancer-related deaths are caused by metastatic disease . Many patients with colon cancer&#xD;
      harbour micrometastases and disseminated tumour cells at the time of surgery . Whether the&#xD;
      micrometastases develop into clinically significant metastases depends on the immune system's&#xD;
      ability to eradicate them.The aim of the study is to declare the effect of&#xD;
      epidural-intravenous based anesthetic technique on anti-tumor immunity and in comparison to&#xD;
      epidural inhalational based anesthetic technique in patients undergoing open surgical&#xD;
      resection of colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group (EP) received epidural - propofol based anesthetic technique and postoperative analgesia through patient controlled epidural analgesia and Group (EH) received epidural- inhalational based anesthetic technique and postoperative analgesia through patient controlled epidural analgesia</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti tumour immunity</measure>
    <time_frame>preoperative and Day 1 postoperatively</time_frame>
    <description>Venous blood samples are withdrawn. Samples for measurement of percentage of expression of CD8,CD16 and CD56 will be collected in sodium heparin anticoagulant tubes and will be processed according to manufacturer's instructions,and samples for VEGF-C will be centrifuged at 4000 g. Thereafter, the serum will be stored at -22 C for future measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in pain intensity</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>pain intensity measured by Visual analogue scale from 0 to 10 where 0 no pain and 10 is sever pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Immunity Factors in Cancer Colon Patients</condition>
  <arm_group>
    <arm_group_label>Group (EP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group (EP) received epidural (fentanyl and bupivacaine) - propofol based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (EH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group (EH) received epidural (fentanyl and bupivacaine)- inhalational based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thoracic epidural</intervention_name>
    <description>undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections</description>
    <arm_group_label>Group (EH)</arm_group_label>
    <arm_group_label>Group (EP)</arm_group_label>
    <other_name>thoracic epidural catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20-70 yrs.&#xD;
&#xD;
          -  ASA class I and II&#xD;
&#xD;
          -  Elective open surgery for non-metastatic cancer colon stage I,II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Known allergy to the study medications&#xD;
&#xD;
          -  Patients with compromised immune function ( associated blood diseases,&#xD;
             immunosuppressive drugs, chemotherapeutic agents, corticosteroids)&#xD;
&#xD;
          -  Contraindications to epidural insertion e.g. infection at insertion site and&#xD;
             coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>samy ab amr, professor</last_name>
    <role>Study Chair</role>
    <affiliation>dean of SECI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Egypt Cancer Institute</name>
      <address>
        <city>Assuit</city>
        <zip>71511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Bahaa Gamal</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

